NCT07331129 The Analgesic Efficacy of Ultrasound Guided Transversalis Fascia Plane Block in Inguinal Lymph Node Dissection
| NCT ID | NCT07331129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Inguinal Lymph Nodes Enlarged |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-12-22 |
| Primary Completion | 2026-06-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-12-22 with a primary completion date of 2026-06-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pain accompanying Inguinal lymph node dissection triggers a complex stress response leading to impairment of pulmonary, immunological and metabolic function. Opioids are the current gold standard drug for postoperative pain relief, however exposure to large doses lead to multiple side effects of varying significance such as nausea, vomiting, dizziness, constipation, respiratory depression, hypoventilation and sleep disordered breathing. Therefore, strategies other than opioids are recommended without sacrificing proper and effective analgesia, especially in cancer patients who are more susceptible to tolerance and addiction. Transversalis Fascia Plane Block is used in patients undergoing various surgeries like iliac crest bone harvesting, appendicectomy, cecostomy and inguinal hernia repair, often in combination with TAP block. The initial description of TFPB was with patients in the supine position, with a linear array or curvilinear probe placed between the iliac crest and the costal margin. The external oblique, internal oblique and transversus abdominis muscles and the transversus aponeurosis are identified. The entry of the needle has to be in-plane, from the anterior aspect, and after traversing through the deep surface of the transversus abdominis muscle, local anesthetic is injected to separate the transversalis fascia from the transversus muscle. Studies have demonstrated that this intervention blocks the proximal branches of T12 and L1 and to a lesser extent T11 in the plane between the transversus abdominis muscle and the transversalis fascia. Since its initial description, ultrasound (US)-guided TFPB has been explored in many randomized controlled trials for patients undergoing iliac crest bone harvesting, lower segment caesarean section (LSCS), inguinal hernia repair and hip surgeries.
Eligibility Criteria
Inclusion Criteria: 1. American society of anesthesiologists (ASA) class I and II. 2. Age ≥ 18 and ≤ 65 Years. 3. Cancer patients for inguinal lymph node dissection. 4. Body mass index (BMI): \> 20 kg/m2 and \< 40 kg/m2. Exclusion Criteria: 1. Patient refusal. 2. Local infection at the puncture site. 3. Coagulopathies with platelets count below 50,000 or an INR\>1.6. 4. Unstable cardiovascular disease. 5. History of psychiatric and cognitive disorders. 6. Patients allergic to medication used.
Contact & Investigator
Ayman Sharawy Abdel Rahman Aboul Nasr, MD
PRINCIPAL INVESTIGATOR
National Cancer Institute Cairo University
Frequently Asked Questions
Who can join the NCT07331129 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Inguinal Lymph Nodes Enlarged. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07331129 currently recruiting?
Yes, NCT07331129 is actively recruiting participants. Contact the research team at ayman.sharawy@nci.cu.edu.eg for enrollment information.
Where is the NCT07331129 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07331129 clinical trial?
NCT07331129 is sponsored by National Cancer Institute, Egypt. The principal investigator is Ayman Sharawy Abdel Rahman Aboul Nasr, MD at National Cancer Institute Cairo University. The trial plans to enroll 90 participants.